Quick Answer
RxSight, Inc. reported Diluted EPS of $0.95 per share (loss) for fiscal year 2025.
RxSight, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.95 | -33.8% |
| 2024 | -$0.71 | +49.6% |
| 2023 | -$1.41 | +41.5% |
| 2022 | -$2.41 | +32.5% |
| 2021 | -$3.57 | -2480.0% |
| 2020 | $0.15 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.24 | -50.0% | +17.2% |
| June 30, 2025 | -$0.29 | -81.2% | -45.0% |
| March 31, 2025 | -$0.20 | +20.0% | -25.0% |
| September 30, 2024 | -$0.16 | +54.3% | +0.0% |
| June 30, 2024 | -$0.16 | +60.0% | +36.0% |
| March 31, 2024 | -$0.25 | +40.5% | +28.6% |
| September 30, 2023 | -$0.35 | +42.6% | +12.5% |
| June 30, 2023 | -$0.40 | +34.4% | +4.8% |
- RxSight, Inc. showed a decrease of -33.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, RxSight, Inc.’s diluted eps has declined by 733.3% (from $0.15 per share to $0.95 per share (loss)).
- The most recent figure is from RxSight, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: